Skip to search formSkip to main contentSkip to account menu

intetumumab

Known as: monoclonal antibody CNTO 95, Human Monoclonal CNTO 95 gamma1 heavy chain (222-215')-disulfide with Human Monoclonal CNTO 95 kappa light chain dimer (228-228'':231-231'')-bisdisulfide, CNTO-95 
A pan alpha-v human monoclonal antibody that recognizes alpha-v beta-1, alpha-v beta-3, alpha-v beta-5, and alpha-v beta-6 integrins with… 
National Institutes of Health

Related topics

Related topics

3 relations
ITGA5 protein, humanantigen binding

Broader (1)

Monoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Randomized phase II study of the safety and efficacy of a human anti-{alpha}v integrin monoclonal antibody (CNTO 95) alone and in combination with dacarbazine in patients with stage IV metastatic…
9029 Objectives: Evaluate the safety and efficacy of CNTO 95, a human anti-αv integrin monoclonal antibody, when administered… 
2015
2015
Bioactivity behaviour of nano-hydroxyapatite/freestanding aligned carbon nanotube oxide composite
Bioactive and low cytotoxic three dimensional nano-hydroxyapatite (nHAp) and aligned carbon nanotube oxide (a-CNTO) composite has… 
2015
2015
A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors
PurposeInhibition of tumor angiogenesis is an effective mechanism to limit tumor growth; dual inhibition may result in additional… 
2013
2013
The effect of alpha-v integrin inhibition on the malignant characteristics of medulloblastoma.
OBJECT Hypoxia induces an aggressive phenotype in some brain tumors in part due to hypoxia-inducible factor-1α (HIF-1α) and… 
2012
2012
211 SPON2, a Newly Identified Transcriptional Target Gene of MACC1, is Associated with Colorectal Cancer Metastasis
2010
2010
Pharmacology and placental transfer of a human alphav integrin monoclonal antibody in rabbits.
BACKGROUND Intetumumab is a human IgG1 anti-alphav-integrin monoclonal antibody that inhibits angiogenesis. Integrin binding and… 
2007
2007
αv Integrin-Targeted Immunoconjugates Regress Established Human Tumors in Xenograft Models
Purpose: Targeted delivery of cytotoxic agents to solid tumors through cell surface antigens can potentially reduce systemic… 
2007
2007
Phase I study of CNTO 95, a fully human monoclonal antibody to αv integrins, docetaxel, and prednisone in hormone refractory prostate cancer patients (HRPCP)
15595 Background: CNTO 95 has demonstrated preclinical antitumor activity through binding to multiple av integrins, resulting in… 
2004
2004
Phase I study of CNTO 95, a fully human monoclonal antibody (mAb) to αv integrins, in patients with solid tumors.
3119 Background: Integrins of the αv family are implicated in tumor angiogenesis and growth. CNTO 95 is a fully human mAb that… 
2004
2004
A rational approach for a phase I clinical study design to evaluate CNTO 95, a novel, fully human anti-avmonoclonal antibody (MAb), in patients with solid tumors.
2609 Background: Centocor has developed a fully human MAb,designated CNTO 95, against avintegrin receptors, known to be essential… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)